Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2061 to 2070 of 2581 total matches.
Kyleena - Another Hormonal IUD
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017 (Issue 1515)
of use.
THE NEW DEVICE — Kyleena has a 30x28-mm T-shaped
polyethylene frame with a drug reservoir ...
The FDA has approved Kyleena (Bayer), an intrauterine
device (IUD) that releases the synthetic progestin
levonorgestrel, for prevention of pregnancy. It is the
fourth levonorgestrel-releasing IUD to be approved in
the US. Like Mirena, which has been available since
2000, Kyleena is approved for up to 5 years of use.
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
effectiveness for extended COVID-19 vaccine schedules in
England. Nat Commun 2021; 12:7217.
1. FDA Drug Safety ...
The CDC has issued new guidance allowing for
an interval of up to 8 weeks between the first and
second primary doses of an mRNA COVID-19 vaccine
in certain patients 12-64 years old.1 Product labeling
currently recommends a 3-week interval between the
first two doses of the Pfizer/BioNTech mRNA vaccine
(Comirnaty) and a 4-week interval between the first
two doses of the Moderna mRNA vaccine (Spikevax).
The new guidance is based on data suggesting that
a longer interval can decrease the risk of myocarditis
and may improve vaccine efficacy.
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
of hematologic
malignancy in patients treated with the gene therapy.
DRUG INTERACTIONS — Hydroxyurea, voxelotor ...
Two cell-based gene therapies – exagamglogene
autotemcel (Casgevy – Vertex) and lovotibeglogene
autotemcel (Lyfgenia – Bluebird Bio) – have been
approved by the FDA for treatment of sickle cell
disease in patients ≥12 years old with recurrent vaso-occlusive
crises. They are the first gene therapies to
be approved in the US for use in sickle cell disease;
Casgevy is the first treatment to be approved in the
US that uses CRISPR/Cas9 gene-editing technology.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):9-10 doi:10.58347/tml.2024.1694a | Show Introduction Hide Introduction
New Ways To Scan The Myocardium
The Medical Letter on Drugs and Therapeutics • Sep 20, 1991 (Issue 853)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Myocardial images produced by injections of radioactive thallium chloride (201Tl), usually during exercise, have been used for many years for diagnosis of coronary artery disease (Medical Letter, 21:49, 1979). Recently, some new techniques and radiopharmaceuticals have become available for myocardial imaging.
Eletriptan (Relpax) for Migraine
The Medical Letter on Drugs and Therapeutics • Apr 28, 2003 (Issue 1155)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
Eletriptan hydrobromide (Relpax Pfizer) is now available in the US for oral treatment of migraine headache in adults. It is the seventh serotonin 5-HT1B/1D-receptor agonist (triptan) to be approved by the FDA for this indication. This review describes the pharmacokinetics, adverse effects, drug interactions and recommended dosage of eletriptan. Clinical trials comparing the new drug to placebo and to sumatriptan are presented. A dosage and cost table for all the triptans available in the US is also included. The review concludes with an overall assessment of eletriptan's efficacy and...
Ophthalmic Moxifloxacin (Vigamox) and Gatifloxacin (Zymar)
The Medical Letter on Drugs and Therapeutics • Mar 29, 2004 (Issue 1179)
drugs achieve high concentrations in the eye that may be effective clinically even when the
organisms ...
Two new fluoroquinolone solutions, moxifloxacin 0.5% (Vigamox - Alcon) and gatifloxacin 0.3% (Zymar - Allergan) are now available in the US for ophthalmic use in treatment of bacterial conjunctivitis.
What About Celebrex?
The Medical Letter on Drugs and Therapeutics • Oct 25, 2004 (Issue 1194)
in highrisk patients will begin in 2005. PAGE 87
The Medical Letter
®
On Drugs and Therapeutics
Rofecoxib ...
Rofecoxib (Vioxx - Merck) has been withdrawn from the market due to an increased risk of cardiovascular complications associated with its long-term use. The question remains whether all selective COX-2 inhibitors carry the same risk. Full-page advertisements in newspapers for celecoxib (Celebrex - Pfizer), the most widely used COX-2 inhibitor, assure the public that it does not.
Prostate Cancer Screening
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008 (Issue 1298)
Letter
®
On Drugs and Therapeutics
Volume 50 (Issue 1298)
November 3, 2008
www.medicalletter.org ...
The US Preventive Services Task Force (USPSTF) has recently concluded that available evidence is insufficient to assess the balance between potential benefits and harms of using the prostate-specific antigen (PSA) to screen men < 75 years old for prostate cancer and has recommended against screening men > 75 years old.
Red Yeast Rice
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009 (Issue 1320)
The Medical Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 ...
Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product to lower cholesterol.
Hyperbaric Oxygen Therapy for Refractory Wounds
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
The Medical Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 ...
Hyperbaric oxygen (HBO2) therapy, breathing 100% O2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot ulcers.